- Cierre anterior
280,76 - Abrir
242,49 - Oferta --
- Precio de compra --
- Rango diario
220,51 - 242,72 - Intervalo de 52 semanas
220,51 - 347,72 - Volumen
6.165.406 - Prom. volumen
679.551 - Capitalización de mercado (intradía)
23,179MM - Beta (5 años al mes) 1,22
- Ratio precio/beneficio (TMTM)
24,69 - BPA (TTM):
8,98 - Fecha de beneficios 23 oct 2024
- Previsión de rentabilidad y dividendo --
- Fecha de exdividendo --
- Objetivo est 1a
321,35
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.
www.iconplc.com42.250
Empleados a tiempo completo
31 de diciembre
Año fiscal finalizado
Healthcare
Sector
Diagnostics & Research
Sector
Noticias recientes: ICLR
Ver más
Descripción general del rendimiento: ICLR
Rentabilidad total acumulada hasta el 24/10/2024, que puede incluir dividendos u otras distribuciones. El valor de referencia es
.Rentabilidad hasta la fecha
Rendimiento en 1 año(s)
Rendimiento en 3 año(s)
Rendimiento en 5 año(s)
Comparar con: ICLR
Selecciona hasta 4 acciones para analizar empresas similares utilizando métricas clave de rendimiento.
Estadísticas: ICLR
Ver másMedidas de valoración
Capitalización de mercado
18.31B
Valor de empresa
21.19B
P/E últimos 12 meses
24.66
Precio/beneficio anticipado
13.53
Ratio precio-expectativas de beneficio (5 años previstos)
0.82
Precio/ventas (ttm)
2.22
Precio/valor (tmr)
1.87
Valor/Ingresos de la empresa
2.55
Valor/EBITDA de empresa
13.33
Destacados financieros
Rentabilidad y estado de resultados
Margen de beneficios
9,00%
Rentabilidad económica (ttm)
4,17%
Rentabilidad financiera (ttm)
7,99%
Ingresos (ttm)
8,31MM
Ingresos netos disponibles (ttm)
747,89M
BPA diluido (ttm)
8,98
Hoja de balance y flujo de caja
Efectivo total (tmr)
695,51M
Endeudamiento/Patrimonio total (tmr)
36,60%
Flujo de efectivo apalancado (ttm)
1,11MM